Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
Corporate Governance
Resources

News Releases

Year

Oct 14 / 26

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

Oct 01 / 26

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Sep 28 / 26

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Sep 08 / 26

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

Sep 01 / 26

Belite Bio to Participate in Four Upcoming Investor Conferences

Aug 24 / 26

Belite Bio to Host Virtual Commercial Day on September 2, 2026

Aug 21 / 26

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Aug 12 / 26

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 11 / 26

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 9 of 29

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio